Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
426 Views
Emedinexus 20 May 2025
The FDA has approved Emrelis, a lyophilized powder for injection, for the treatment of non-squamous non-small cell lung cancer (NSCLC) in patients with high c-Met protein overexpression. Emrelis is a first-in-class antibody-drug conjugate targeting the c-Met protein, offering a new therapeutic option for this aggressive cancer subtype.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}